FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL					
OMB	3235-				
Number:	0104				
Estimated average					
burden hours per					
response	0.5				

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)								
1. Name and Address of Reporting	2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol					ing Symbol		
Person *	Statement	()	AxoGen, Inc. [LECT]					
Grooms Jamie Mark	(Month/Day/Y 09/30/2011	ear)						
(Last) (First) (Middle)	07/30/2011					5. If Amendment, Date Original		
C/O AXOGEN, INC., 13859			× /			Filed(Month/Day/Year)		
PROGRESS BOULEVARD,			(Check all applicable) X Director 10% Owner					
SUITE 100			Officer (give Other (specify					
(Street)			title below) below)			6. Individual or Joint/Group		
						Filing(Check Applicable Line)		
ALACHUA, FL 32615						_X_ Form filed by One Reporting Person Form filed by More than One		
						Reporting Person		
(City) (State) (Zip)	Table I - Non-Derivative Securities Beneficially Owned							
1.Title of Security		2. Amount of	Securities	3.	4. Nati	ure of Indirect Beneficial		
(Instr. 4)		Beneficially C	Owned	Ownership Owne		ership		
		(Instr. 4)		Form: Direct	(Instr.	5)		
				(D) or				
				Indirect (I) (Instr. 5)				
		(4)		,				
Common Stock 213,079 (1)			D					
Common Stock 132,883 (1)			I	See Footnote (2)				
D 1 D 1 C	1 1 6	1	11 1 1 1	.1 ' 1'	.1	OFC 1472 (7.02)		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.	SEC 1473 (7-02
Persons who respond to the collection of information contained in this form are not	
required to respond unless the form displays a currently valid OMB control	
number.	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

(Instr. 4) Expiration Date (Month/Day/Year) S		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	Expiration Date	7 7	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)	
Stock Option	12/05/2007	12/06/2017	Common Stock	11,182 (3) (4) (8)	\$ 0.25	D	
Stock Option	12/06/2007	12/06/2017	Common Stock	3,197 ⁽³⁾ ⁽⁵⁾ ⁽⁸⁾	\$ 0.25	D	
Stock Option	11/18/2008	11/18/2018		494 ⁽³⁾ (6) (8)	\$ 0.25	D	
Stock Option	06/09/2010	06/09/2020		108,989 (3) (7) (8)	\$ 0.25	D	

Reporting Owners

Reporting Owner Name / Address	Keiationsnips				
	Director	10% Owner	Officer	Other	
Grooms Jamie Mark C/O AXOGEN, INC. 13859 PROGRESS BOULEVARD, SUITE 100 ALACHUA, FL 32615	X				

Signatures

/s/ Jamie M. Grooms	10/11/2011
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

 Pursuant to an Agreement and Plan of Merger, dated as of May 31, 2011, by and among LecTec Corporation ("LecTec"), Nerve Merger Sub Corp., a subsidiary of LecTec ("Merger Sub"), and AxoGen Corporation ("AC"), which the parties amended on June 30, 2011 and
- (1) August 9, 2011 (as amended, the "Merger Agreement"), Merger Sub merged with and into AC, with AC continuing after the merger as the surviving corporation and a wholly owned subsidiary of LecTec (the "Merger"). The Merger was completed on September 30, 2011, and LecTec was renamed AxoGen, Inc. ("AxoGen"). In connection with the Merger, each share of AC common stock converted into 0.03727336 share of LecTec common stock at the effective time of the Merger.
- (2) These shares are directly owned by the Jamie Grooms Trust, of which Mr. Grooms is the trustee.
- (3) In connection with the Merger, each option to purchase shares of AC common stock was converted to an option to purchase 0.03727336 of a share of AxoGen common stock.
- (4) 9,799 options have vested, and 1,383 options are unvested.
- (5) 2,797 options have vested, and 400 options are unvested.
- (6) 309 options have vested, and 185 options are unvested.
- (7) 27,247 options have vested, and 81,742 options are unvested.
- (8) These options vest semi-annually over four years from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.